Continuing education (CE) information for credit

Navigating Therapeutic Uncertainties: A Review of Recent Vizient Expert Panels

Activity date: October 21, 2022

Course director: Gretchen Brummel

Vizient is committed to complying with the criteria set forth by the accrediting agencies in order to provide this quality course. To receive credit for educational activities, you must successfully complete all course requirements.

**Requirements**

1. Attend the course in its entirety.
2. After the course, you will receive an email with instructions that you will need to obtain your CE credit.
3. **Complete the process no later December 5, 2012.**

Upon successful completion of the course requirements, you will be able to print your CE certificate (with the exception of pharmacists and pharmacy technicians.)

**Important note for pharmacists and pharmacy technicians**

All credit awarded to pharmacists and pharmacy technicians must be via CPE Monitor; paper certificates and e-certificates are not valid for licensure/certification submission. Pharmacists and pharmacy technicians will be able to print individual statements of credit and their transcripts from their NABP e-profile created at [www.mycpemonitor.net](http://www.mycpemonitor.net) or [www.nabp.net](http://www.nabp.net).

1. Please provide an accurate **NABP ID number** and **date of birth** (**mm/dd** – do not include birth year).
2. Vizient will upload your **NABP ID number** and **date of birth** into CPE Monitor within 24 hours after the completion of all steps required to receive credit.

If your **NABP ID number** and/or **date of birth** are returned as invalid after the upload, Vizient will make one attempt to contact you for corrections within a 45-day window. After the 45-day window expires, Vizient will not accept the information, and Vizient will not be able to process your CE credit.

**Pharmacists learning objectives**

At the conclusion of this activity, pharmacists should be able to:

1. Describe the Expert Panel process
2. Describe the therapeutic controversies and/or gaps in the literature around the use of tenecteplase vs alteplase in acute ischemic stroke and long-acting bupivacaine products for postsurgical analgesia
3. Discuss the results of the Expert Panels for tenecteplase vs alteplase in acute ischemic stroke and long-acting bupivacaine products for postsurgical analgesia

**Joint Accreditation Statement:**



In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 (ANCC), to provide continuing education for the healthcare team.

**Designation Statement(s):**

#### PHARMACY

Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.

UAN JA0006103-0000-22-069-L01-P

**Identification, Mitigation, and Disclosure of Relevant Financial Relationships**

As an accredited provider of continuing education**,** Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

**Disclosure of Financial Relationships:**

**Absence of Relevant Financial Relationships**

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.

### Faculty

### John Schoen, PharmD, BCPS

### Sr Clinical Manger, Drug Information

### Vizient

### Kyle Hoelting, PharmD, BCPS

### Sr Clinical Manger, Drug Information

### Vizient

### Planning committee

### Jackie Stokes, BS

### Manager, Pharmacy Program

### Vizient

### Gretchen Brummel, PharmD, BCPS

### Consulting Solutions Director

### Vizient

### Statement of content validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

**FDA off-label/unapproved usage**

Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.

Usage Disclosure: “**Off-label/unapproved drug uses or products are mentioned within this activity.**”

Evidence-based Content: **“Low/absence of evidence-based topics are mentioned within this activity”**

**Disclaimer:** The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.